CN112618713A - anti-HPV and anti-gynecological inflammation composite ovovitellin composition and gel - Google Patents
anti-HPV and anti-gynecological inflammation composite ovovitellin composition and gel Download PDFInfo
- Publication number
- CN112618713A CN112618713A CN202110013324.9A CN202110013324A CN112618713A CN 112618713 A CN112618713 A CN 112618713A CN 202110013324 A CN202110013324 A CN 202110013324A CN 112618713 A CN112618713 A CN 112618713A
- Authority
- CN
- China
- Prior art keywords
- hpv
- ovoglobulin
- ovomyosin
- type
- gynecological
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Inorganic Chemistry (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The embodiment of the invention discloses an anti-HPV and anti-gynecological inflammation composite ovovitellin composition and a gel, which comprises the following raw materials in percentage by weight: 0.1-3% of anti-human papilloma virus ovovitellin, 0.1-3% of anti-gynecological inflammation ovovitellin, 0.5-5% of carbomer and the balance of preservative and auxiliary materials. The anti-human papilloma virus ovomyosin is added with the composite anti-gynecological inflammation ovomyosin to form the antibody cocktail therapy, so that the Human Papilloma Virus (HPV) and the gynecological inflammation virus can be effectively neutralized.
Description
Technical Field
The embodiment of the invention relates to the technical field of medical treatment and health, and in particular relates to an anti-HPV and anti-gynecological inflammation composite ovomyosin composition and a gel.
Background
The cervical cancer is a gynecological malignant tumor with the incidence rate of 2 nd next to that of breast cancer in China, and is the only cancer with definite etiology in the world at present, Human Papilloma Virus (HPV) infection is generally considered to be an important factor causing cervical canceration at present, but HPV infection is not the only factor causing cervical canceration, and besides HPV infection, chronic inflammation of the cervix caused by the reproductive system is also an independent risk factor inducing the cervical cancer. Therefore, elimination of female gynecological inflammation pathogenic bacteria and HPV virus is the most effective measure for effectively preventing cervical cancer. The embodiment of the invention provides a composite ovovitellin composition for resisting human papilloma virus and gynecological inflammation, which can effectively neutralize Human Papilloma Virus (HPV) and gynecological inflammation virus.
Disclosure of Invention
Therefore, the embodiment of the invention provides an anti-HPV and anti-gynecological inflammation compound ovovitellin composition and a gel, which can effectively neutralize Human Papilloma Virus (HPV) and gynecological inflammation virus.
In order to achieve the above object, the embodiments of the present invention provide the following technical solutions:
according to the first aspect of the embodiments of the present invention, a composite ovovitellin composition for resisting human papilloma virus and gynecological inflammation is provided, which comprises the following raw materials by weight: 0.1-3% of anti-human papilloma virus ovovitellin, 0.1-3% of anti-gynecological inflammation ovovitellin, 0.5-5% of carbomer and the balance of preservative and auxiliary materials.
Further, the auxiliary materials comprise glycerol and purified water.
Further, the anti-human papillomavirus ovoglobulin includes anti-HPV 6 type ovoglobulin, anti-HPV 11 type ovoglobulin, anti-HPV 16 type ovoglobulin, anti-HPV 18 type ovoglobulin, anti-HPV 31 type ovoglobulin, anti-HPV 33 type ovoglobulin, anti-HPV 45 type ovoglobulin, anti-HPV 52 type ovoglobulin, anti-HPV 58 type ovoglobulin, anti-HPV 65 type ovoglobulin, anti-HPV 81 type ovoglobulin.
Further, the anti-gynecological inflammation ovomyosin comprises anti-staphylococcal ovomyosin, anti-streptococcal ovomyosin, anti-colibacillus ovomyosin and anti-candida egg yolk globulin.
Further, the anti-human papilloma virus ovomyosin and the anti-gynecological inflammation ovomyosin are wrapped in the nano lipid carrier.
Further, the nano lipid carrier comprises lecithin.
According to a second aspect of the embodiments of the present invention, there is provided an anti-HPV and anti-gynecological inflammation complex ovomyosin gel made of the anti-HPV and anti-gynecological inflammation complex ovomyosin composition as defined in any one of the above.
The embodiment of the invention has the following advantages:
the invention provides a composite ovovitellin composition and gel for resisting human papilloma virus and gynecological inflammation, which comprises the following raw materials in percentage by weight: 0.1-3% of anti-human papilloma virus ovovitellin, 0.1-3% of anti-gynecological inflammation ovovitellin, 0.5-5% of carbomer and the balance of preservative and auxiliary materials. The anti-human papilloma virus ovomyosin is added with the composite anti-gynecological inflammation ovomyosin to form the antibody cocktail therapy, so that the Human Papilloma Virus (HPV) and the gynecological inflammation virus can be effectively neutralized.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below. It should be apparent that the drawings in the following description are merely exemplary, and that other embodiments can be derived from the drawings provided by those of ordinary skill in the art without inventive effort.
FIG. 1 shows the detection result of the HPV antigen activity of the anti-HPV and anti-gynecological inflammation compound ovomyosin freeze-dried powder composition provided in example 1 of the invention;
FIG. 2 shows the result of the detection of the anti-HPV and anti-gynecological inflammation complex ovomyosin gel combined with HPV antigen activity provided in example 1 of the present invention.
Detailed Description
The present invention is described in terms of particular embodiments, other advantages and features of the invention will become apparent to those skilled in the art from the following disclosure, and it is to be understood that the described embodiments are merely exemplary of the invention and that it is not intended to limit the invention to the particular embodiments disclosed. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The embodiment 1 of the invention provides a composite ovovitellin composition for resisting human papilloma viruses and gynecological inflammation, which comprises the following raw materials in percentage by weight: 0.1-3% of anti-human papilloma virus ovovitellin (IgY), 0.1-3% of anti-gynecological inflammation ovovitellin (IgY), 0.5-5% of carbomer and the balance of preservative and auxiliary materials.
In this embodiment, the auxiliary materials include glycerin and purified water.
In this example, anti-HPV ovomyosin includes anti-HPV 6 type ovomyosin, anti-HPV 11 type ovomyosin, anti-HPV 16 type ovomyosin, anti-HPV 18 type ovomyosin, anti-HPV 31 type ovomyosin, anti-HPV 33 type ovomyosin, anti-HPV 45 type ovomyosin, anti-HPV 52 type ovomyosin, anti-HPV 58 type ovomyosin, anti-HPV 65 type ovomyosin, anti-HPV 81 type ovomyosin. The gynecological inflammation resisting yolk globulin includes anti-staphylococcal yolk globulin, anti-streptococcal yolk globulin, anti-colibacillus yolk globulin, and anti-candida yolk globulin.
In the embodiment, the anti-human papilloma virus and anti-gynecological inflammation lecitins are wrapped in a nano lipid carrier, and the nano lipid carrier comprises lecithin.
An anti-HPV and anti-gynecological inflammation compound ovomyosin gel is prepared from the anti-HPV and anti-gynecological inflammation compound ovomyosin composition.
The preparation method of the anti-HPV and anti-gynecological inflammation composite ovovitellin gel comprises the following steps:
1) typical human papilloma virus and typical gynecological inflammation virus are screened.
The virus early genes E6 and E7 are expressed in eukaryotic cells or prokaryotic cells, self-assembled into virus-like particles and purified to obtain the purified virus-like particles, namely the human papilloma virus.
In this example, the types of human papillomaviruses include HPV6, HPV11, HPV16, HPV18, HPV31, HPV33, HPV45, HPV52, HPV58, HPV65, and HPV 81. The gynecological inflammation virus includes Staphylococcus, Streptococcus, Escherichia coli, and Candida.
2) Injecting the obtained high-activity high-purity human papilloma virus and gynecological inflammation virus of different types into SPF chicken together with adjuvants respectively, and exciting to generate antiviral ovomyosin against different types of viruses to obtain eggs containing different antiviral ovomyosin.
In this embodiment, the composite immunoadjuvant includes R71 adjuvant, freund's adjuvant, aluminum salt adjuvant, and the like.
Each virus, type, was injected independently, and each chicken received only one virus injection, resulting in only one antiviral ovalbumin. When the virus is injected into the chicken, the adjuvant is added, so that the antibody produced in the chicken is the most and the activity is the highest.
3) The obtained eggs are crushed, separated, purified, freeze-dried and mixed to obtain the high-purity anti-HPV and anti-gynecological inflammation composite ovomyosin freeze-dried powder.
Each chicken only produces single antibody corresponding to the injection type, and the single ovoglobulin is respectively purified, lyophilized and mixed to obtain the composite ovoglobulin.
4) The anti-HPV and anti-gynecological inflammation composite ovomyosin freeze-dried powder is wrapped in the nano lipid carrier through high-speed rotation. The antibody is wrapped in a nano lipid carrier so as to facilitate membrane penetration and better absorption.
5) Sequentially adding the composite ovoglobulin freeze-dried powder, carbomer, preservative and auxiliary materials wrapped in the nano lipid carrier into an emulsifying machine, and stirring by a scraping frame type stirrer and a paddle type stirrer until the mixture is uniformly stirred and has no bubbles to obtain the gel.
In the step 5), a vacuum pump is used for exhausting bubbles in the raw materials in the stirring process, and the liquid level position in the tank body is noticed during operation, so that the vacuum pump is prevented from pumping the raw materials out.
Examples of the experiments
The neutralization effect of the anti-HPV and anti-gynecological inflammation composite ovoglobulin lyophilized powder composition and the prepared anti-HPV and anti-gynecological inflammation composite ovoglobulin gel on HPV virus is detected by an Elisa method, and as shown in figures 1 and 2, the test results show that the composite ovoglobulin composition and gel in the embodiment can effectively neutralize human papilloma virus HPV.
According to the anti-HPV and anti-gynecological inflammation composite ovomyosin composition and gel provided by the embodiment of the invention, anti-HPV and anti-gynecological inflammation composite ovomyosin is compounded through anti-human papilloma virus ovomyosin to form an antibody cocktail therapy, and IgY antibody is carried and protected by a nano lipid carrier to directly reach basal cells, so that Human Papilloma Virus (HPV) and gynecological inflammation virus can be effectively neutralized.
Although the invention has been described in detail above with reference to a general description and specific examples, it will be apparent to one skilled in the art that modifications or improvements may be made thereto based on the invention. Accordingly, such modifications and improvements are intended to be within the scope of the invention as claimed.
Claims (7)
1. An anti-HPV and anti-gynecological inflammation composite ovovitellin composition is characterized by comprising the following raw materials in percentage by weight: 0.1-3% of anti-human papilloma virus ovovitellin, 0.1-3% of anti-gynecological inflammation ovovitellin, 0.5-5% of carbomer and the balance of preservative and auxiliary materials.
2. The anti-HPV and anti-gynecological-inflammation composite ovovitellin composition according to claim 1, wherein the auxiliary materials comprise glycerol and purified water.
3. The anti-HPV and anti-gynecological inflammation complex ovoglobulin composition according to claim 1, wherein said anti-human papillomavirus ovoglobulin comprises anti-HPV 6 type ovoglobulin, anti-HPV 11 type ovoglobulin, anti-HPV 16 type ovoglobulin, anti-HPV 18 type ovoglobulin, anti-HPV 31 type ovoglobulin, anti-HPV 33 type ovoglobulin, anti-HPV 45 type ovoglobulin, anti-HPV 52 type ovoglobulin, anti-HPV 58 type ovoglobulin, anti-HPV 65 type ovoglobulin, anti-HPV 81 type ovoglobulin.
4. The anti-HPV and anti-gynecological-inflammation composite ovomyosin composition according to claim 1, characterized in that the anti-gynecological-inflammation ovomyosin comprises anti-staphylococcal ovomyosin, anti-streptococcal ovomyosin, anti-colibacillus ovomyosin, anti-candida ovoglobulin.
5. The anti-HPV and anti-gynecological-inflammation composite ovomyosin composition according to claim 1, characterized in that the anti-human papilloma virus ovomyosin and the anti-gynecological-inflammation ovomyosin are wrapped in a nano lipid carrier.
6. The anti-HPV and anti-gynecological-inflammation complex lecithin composition according to claim 5, wherein the nano-lipid carrier comprises lecithin.
7. An anti-HPV and anti-gynecological inflammation complex ovomyosin gel, characterized in that it is made from a composition according to any one of claims 1-6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110013324.9A CN112618713A (en) | 2021-01-06 | 2021-01-06 | anti-HPV and anti-gynecological inflammation composite ovovitellin composition and gel |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110013324.9A CN112618713A (en) | 2021-01-06 | 2021-01-06 | anti-HPV and anti-gynecological inflammation composite ovovitellin composition and gel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112618713A true CN112618713A (en) | 2021-04-09 |
Family
ID=75291570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110013324.9A Pending CN112618713A (en) | 2021-01-06 | 2021-01-06 | anti-HPV and anti-gynecological inflammation composite ovovitellin composition and gel |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112618713A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113559260A (en) * | 2021-08-17 | 2021-10-29 | 深圳市中康天使物联网有限公司 | anti-Human Papilloma Virus (HPV) e6e7 private gel component and production process thereof |
| CN114146213A (en) * | 2021-12-06 | 2022-03-08 | 广西博生生物科技有限公司 | Gel dressing of composite yolk globulin gamma protein and preparation method and application thereof |
| CN114569717A (en) * | 2022-03-05 | 2022-06-03 | 广西博生生物科技有限公司 | anti-HPV virus yolk immunoglobulin gel and preparation method thereof |
-
2021
- 2021-01-06 CN CN202110013324.9A patent/CN112618713A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113559260A (en) * | 2021-08-17 | 2021-10-29 | 深圳市中康天使物联网有限公司 | anti-Human Papilloma Virus (HPV) e6e7 private gel component and production process thereof |
| CN114146213A (en) * | 2021-12-06 | 2022-03-08 | 广西博生生物科技有限公司 | Gel dressing of composite yolk globulin gamma protein and preparation method and application thereof |
| CN114569717A (en) * | 2022-03-05 | 2022-06-03 | 广西博生生物科技有限公司 | anti-HPV virus yolk immunoglobulin gel and preparation method thereof |
| CN114569717B (en) * | 2022-03-05 | 2023-11-14 | 广西博生生物科技有限公司 | Yolk immunoglobulin gel for resisting HPV virus and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112618713A (en) | anti-HPV and anti-gynecological inflammation composite ovovitellin composition and gel | |
| US7815915B2 (en) | Mixture of human papillomavirus virus-like particles | |
| Gambhira et al. | Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2 | |
| Frazer | Interaction of human papillomaviruses with the host immune system: a well evolved relationship | |
| CN112826931A (en) | Preparation method of anti-HPV and anti-gynecological inflammation composite ovovitellin gel | |
| EP2118292B1 (en) | Papillomavirus e2 polypeptide used for vaccination | |
| US20050244432A1 (en) | Vaccine | |
| CA2543928A1 (en) | Optimized expression of hpv 58 l1 in yeast | |
| Kawana et al. | Human papillomavirus vaccines: current issues & future | |
| US10882887B2 (en) | Papillomavirus chimeric protein and application thereof | |
| EP2155240B1 (en) | Intradermal hpv peptide vaccination | |
| RU2005132603A (en) | OPTIMIZED HPV 31 L1 EXPRESSION IN YEAST | |
| RU2006114701A (en) | OPTIMIZED HPV45 L1 EXPRESSION IN YEAST | |
| WO2002090382A3 (en) | Mixture of peptides derived from e6 and/or e7 papillomavirus proteins and uses thereof | |
| EP2589604B1 (en) | Truncated l1 protein of human papillomavirus type 52 | |
| WO2008112125A1 (en) | Papillomavirus vaccine compositions | |
| CN101016542A (en) | Method of increasing yield of human papilloma virus L1 albumen pronucleus expression | |
| Da Silva et al. | Suppression of Langerhans cell activation is conserved amongst human papillomavirus α and β genotypes, but not a µ genotype | |
| Olczak et al. | RG2-VLP: a vaccine designed to broadly protect against anogenital and skin human papillomaviruses causing human cancer | |
| RU97110164A (en) | PREPARED PAPILLOMA VIRUS PROTEINS | |
| US6280740B1 (en) | Formulations of recombinant papillomavirus vaccines | |
| Vardy et al. | The cellular immune response to human papillomavirus infection. | |
| CN101116745B (en) | Human papilloma virus sample particle vaccines | |
| CN102181426A (en) | Expression and application of human papilloma virus type16 and 18 L1 protein in yeast | |
| JP2013540421A5 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |